Not All Seeds Are Created Equal
Cancer Treatment with Cesium-131 Brachytherapy Seeds by Isoray
Not all seed brachytherapy radioisotopes are the same. You and your doctor should choose the best isotope for your cancer treatment. Ask your doctor about Cesium-131 by Isoray.
Improved Coverage of the Prostate
Rapid Resolution of Side effects
Higher Biologically Effective Dose
“Cesium makes a good doc an even better doc.”
WHY CESIUM-131 BY ISORAY?
With a shorter half-life and higher energy than other commonly used radioisotopes, Cesium-131 by Isoray has been shown to be a highly effective cancer treatment when planned appropriately. (10, 14, 17)
- Quick Recovery
- Speedy Return to PSA Baseline
Your Isotope Choice Makes a Difference
Cesium-131Introduced in 2004
9.7 Day Half Life
The amount of time for the radiation to half. A shorter half life means quicker to PSA baseline. (8, 12, 13)
The energy level of the isotope. Higher energy leads to greater coverage of the infected organ.
33 Days for 90% Dose
Faster dose delivery rate.
115 Gy Total Dose
The amount of dose. A lower dose means less total radiation used to treat your cancer.
Detectable in the body for 97 Days
Paladium-103Introduced in 1986
17 Day Half Life (18)
58 Days for 90% Dose
125 Gy Total Dose
Detectable in the body for 170 Days
Iodine-125Introduced in 1965
60 Day Half Life (18)
204 Days for 90% Dose
145 Gy Total Dose
Detectable in the body for 600 Days
Armpilla C, Dale R, Coles I, et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Rad Onc Biol Phys 2003; 55:378-385.
Patients & Families
Find a Doctor Near You
A diagnosis is just the first step toward treating your cancer. We are here to help you make an informed treatment decision with your doctor so you can begin living your life again.
2. Neill B, et al. The Nature and Extent of Urinary Morbidity in Relation to Prostate Brachytherapy Urethral Dosimetry. Brachytherapy 2007:6(3)173-9.
3. Musmacher JS, et al. Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy. Int. J. Radiation Oncology Biol. Phys. 2007:69(3)S730-1.
4. Yaparpalvi R, et al. Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy? A Dosimetric View Point. Int. J. Radiation Oncology Biol. Phys. 2007:69(3)S677-8.
5. Sutlief S, et al. Cs-131 Prostate Brachytherapy and Treatment Plan Parameters. Medical Physics 2007:34(6)2431.
6. Yang R, et al. Dosimetric Comparison of Permanent Prostate Brachytherapy Plans Utilizing Cs-131, I-125 and Pd-103 Seeds. Medical Physics 2008:35(6)2734.
7. Prestidge B, et. al. Clinical Outcomes of a Phase-II, Multi-institutional Cesium-131 Permanent Prostate Brachytherapy Trial. Brachytherapy. 2007: 6 (2)78.
8. Moran B, et al. Cesium-131 Prostate Brachytherapy: An Early Experience. Brachytherapy 2007:6(2)80.
9. Jones A, et al. IPSS Trends for Cs-131 Permanent Prostate Brachytherapy. Brachytherapy 2008:7(2)194.
10. DeFoe SG, et al. Is There Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Radioisotope? Int. J. Radiation Oncology Biol. Phys. 2008:72(S1)S317.
11. Armpilia CI, Dale RG, Coles IP et al. The Determination of Radiobiologically Optimized Half-lives for Radionuclides Used in Permanent Brachytherapy Implants. Int. J. Radiation Oncology Biol. Phys. 2003; 55 (2): 378-385.
12. Bice W, et. al. Recommendations for permanent prostate brachytherapy with 131Cs: a consensus report from the Cesium Advisory Group. Brachytherapy 2008:7(4)290-296.
13. Platta CS, et al. Early Outcomes of Prostate Seed Implants with 131Cs: Toxicity and Initial PSA Dynamics from a Single Institution. Int. J. Radiation Oncology Biol. Phys. 2008:72(S1)S323-4.
14. Tomaszewski JJ, et al. Cesium 131 versus iodine 125 implants for prostate cancer: evaluation of early PSA response. The Canadian Journal of Urology. 2010;17(5): 5360-5364.
15. R.M. Benoit, R.P. Smith, S. Beriwal. Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy. Clinical Oncology. 26 (2014) 776 780.
16. Brian J. Moran, MD, Michelle H. Braccioforte, MPH. Prostate Cancer Foundation of Chicago, Westmont, IL. PSA Outcomes in a Single Institution, Prospective Randomized 131Cs/125I Permanent Prostate Brachytherapy Trial Abstracts / Brachytherapy. 13 (2014) S15eS126.
17. Amit B. Shah, MD, Arnav A. Shah, Gregory A. Fortier, MD. Radiation Oncology, York Cancer Center, Wellspan Health, York, PA. A Comparison of AUA Symptom Scores following Permanent Low-Dose-Rate Prostate Brachytherapy with Iodine-125 and Cesium-131, Abstracts / Brachytherapy 12 (2013) S11eS77.
18. Herstein A, Wallner K, Merrick G, Mitsuyama H, Armstrong J, True L, Cavanagh W, Butler W. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J. 2005 Sep-Oct;11(5):385-9.